Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 1.01
Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants at $3.30 per share, expected to raise approximately $4.1 million in net proceeds. While technically registered (via Form S-3), this is a direct offering to institutional investors with significant warrant dilution (up to 2.7 million additional shares if warrants are exercised), representing material equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-11
Item 8.01
Enliven Therapeutics announced updated positive Phase 1 clinical trial data from the ENABLE trial evaluating ELVN-001 in patients with chronic myeloid leukemia, including key outcomes from an FDA End-of-Phase 1 meeting and selection of the 80 mg QD dose for Phase 3 development. This represents material clinical progress for the company's lead candidate that affects investor assessment of the pipeline and regulatory pathway.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Shattuck Labs entered into an underwriting agreement on June 9, 2026 for a registered public offering of 10.9 million shares of common stock at $4.00 per share, plus 7.9 million pre-funded warrants, with underwriters exercising a full 30-day overallotment option for an additional 2.8 million shares. This is a material dilutive equity issuance that raises capital through the sale of common stock and warrant securities, affecting existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Jaguar Health entered into two material equity financing arrangements on June 9, 2026: a $40 million Equity Line of Credit (ELOC) with an accredited investor and a $2 million Preferred Stock Financing with multiple investors including pre-funded warrants. Both transactions involve unregistered or to-be-registered equity issuances that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 5.03
The company filed a Series P Certificate of Designation establishing the terms of a new preferred stock class with 8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections. These structural provisions create contingent obligations that could materially affect the company's capital structure and shareholder value.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Broadcom announced the launch of cash tender offers for certain debt securities on June 11, 2026. While this is a material capital management activity that would affect investor assessment of the company's financial strategy and debt structure, it does not fit neatly into the more specific event categories (it is not a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, or dilutive equity issuance). Debt tender offers are material refinancing activities but lack a dedicated taxonomy category, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—it describes the mechanism and structure of consolidated obligations rather than disclosing a specific new debt issuance event. The prose emphasizes that Schedule A lists obligations "committed to be issued" and notes the FHLBank has not made materiality judgments on particular obligations. This appears to be a standing disclosure of the FHLBank's debt issuance framework rather than a discrete material event triggering Item 2.03, making it best classified as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 3.02
The Company disclosed the sale of 12,690 Class D Common Shares for $350,000 gross proceeds on June 8, 2026, as part of a continuous private placement offering of up to $2.165 billion in common shares under Section 4(a)(2) and Regulation D Rule 506(c). This is a classic unregistered equity issuance that creates dilution to existing shareholders and is material to investors assessing the registrant's capital structure and future equity dilution risk.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-11
Item 5.02
The filing discloses the appointment of Kevin J. Necas, Jr. as Senior Vice President – Chief Accounting Officer and principal accounting officer effective July 2, 2026. While Michael P. Gallagher's retirement is also mentioned, the principal disclosed action centers on the appointment of Necas to a key financial officer role. The appointment of a principal accounting officer is material to investors as it affects the registrant's financial reporting oversight and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from Airgain's 2026 Annual Meeting held on June 10, 2026. The filing reports final vote tallies for four proposals: election of two Class I directors (Sims and Chung), ratification of Grant Thornton LLP as auditor, advisory approval of named executive officer compensation, and approval of the amended 2016 Incentive Award Plan. All proposals passed. This is a quintessential Item 5.07 shareholder vote results disclosure, material to investors as it confirms governance and compensation decisions.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-11
Item 1.01
Badger Meter amended and extended its $150 million revolving credit facility, with a new maturity date of July 8, 2031. The amendment represents a material refinancing and extension of the company's existing credit facilities, affecting its capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
General Motors Financial Company closed a $1 billion public offering of senior notes due 2031 with net proceeds of approximately $993 million. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy—it is neither a merger/acquisition (ma_activity), a dilutive equity issuance (dilutive_issuance), nor a debt covenant breach (covenant_breach). The disclosure is a routine debt offering, which is material to investors but lacks the specific event-type indicators that would classify it as earnings_release, going_concern, or other defined categories.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-11
Item 1.01
CarMax Select Receivables Trust 2026-B entered into an Underwriting Agreement on June 9, 2026 for the issuance of approximately $570 million in Asset-backed Notes backed by motor vehicle retail installment sale contracts. This material securitization financing transaction involved the creation and sale of securitized receivables through multiple transaction documents, constituting a significant capital event for the trust.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte & Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst & Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
Gladstone Investment Corporation entered into Amendment No. 13 to its credit facility on June 10, 2026, materially restructuring the debt arrangement by extending the revolving period to June 8, 2029, increasing the facility size from $300 million to $405 million (with ability to reach $500 million), and modifying interest rate terms and covenants. This material modification to the company's capital structure and financing arrangements affects investor assessment of liquidity and leverage.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-11
Item 8.01
Western Digital entered into exchange agreements to swap 1,038,681 shares of SanDisk stock for shares of its own common stock held by institutional investors. This constitutes a material disposition of a significant equity stake (over 1 million shares) in a subsidiary/affiliate, which qualifies as M&A activity under Item 1.01/2.01 framework. The transaction involves a material change in the company's asset composition and shareholder base.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 filing discloses the final voting results from Heritage Insurance Holdings' annual meeting of stockholders held on June 10, 2026. The section presents results for four proposals: election of six directors, ratification of Plante & Moran as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. These are routine shareholder meeting outcomes that materially inform investors about governance and board composition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-11
Item 1.01
Parabilis entered into a Stock Purchase Agreement with Regeneron for a private placement of 4,166,666 shares at $18.00 per share, concurrent with the Company's IPO on June 11, 2026. The unregistered private placement under Section 4(a)(2) and Regulation D includes piggyback registration rights for Regeneron and dilutes existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Alphatec held its June 10, 2026 Annual Meeting of Stockholders, at which shareholders voted on five proposals: election of seven directors, ratification of Deloitte & Touche LLP as auditor, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from an Annual Meeting under Item 5.07. The filing reports final voting tallies for three proposals: election of three directors (Chris Cain, Arlene Morris, and Todd Shegog), ratification of PricewaterhouseCoopers LLP as independent auditor, and an advisory vote on executive compensation. All proposals passed. This is a material event as it confirms the composition of the board and auditor selection, both of which affect investor assessment of governance and financial oversight.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-11
Item 5.02
Universal Health Realty Income Trust granted restricted stock awards to four named executive officers on June 10, 2026, with specified share quantities and vesting terms as part of the company's annual long-term incentive compensation program.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Shareholders of Universal Health Realty Income Trust voted at the June 10, 2026 Annual Meeting on three proposals: election of two Class I trustees (Alan B. Miller and Robert F. McCadden), a nonbinding advisory vote on named executive officer compensation, and ratification of KPMG, LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 99%
filed 2026-06-11
Item 5.07
Alphabet Inc. held its 2026 Annual Meeting of Shareholders on June 5, 2026, with voting results disclosed for fourteen proposals including director elections (Larry Page, Sergey Brin, Sundar Pichai, and others), ratification of Ernst & Young LLP as auditor, approval of stock plan amendments, advisory vote on executive compensation, and multiple shareholder proposals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-11
Item 1.01
Ciena closed a $2.875 billion private offering of convertible senior notes on June 11, 2026, receiving net proceeds of approximately $2.72 billion. The company used proceeds to repay $1.14 billion of existing debt and repurchase shares, representing a significant capital structure and financing transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-11
Item 3.02
Ciena sold convertible senior notes and warrants in unregistered transactions under Section 4(a)(2) and Rule 144A, with up to 7,700,978 shares of common stock issuable upon exercise of the warrants. The offering included convertible note hedge and warrant transactions, creating material share dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-06-11
Item 1.01
Dana entered into definitive agreements with Eaton Corporation for a Reverse Morris Trust transaction involving a restructuring, distribution of SpinCo (Eaton's Vehicle and eMobility business), and merger of Dana into SpinCo, resulting in Dana becoming a wholly-owned subsidiary of SpinCo. This is a material change of control transaction unanimously approved by both boards, with former Dana shareholders owning approximately 49.9% of the combined entity post-closing. The transaction involves substantial asset transfers, a $1.1 billion cash payment, and $2.6 billion in bridge financing.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Jade Biosciences held its 2026 Annual Meeting of Stockholders with voting results on the election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-11
Item 5.02
The filing's primary focus is the approval of cash retention payments and amended "Change in Control" benefits for named executives (Sapir, Oltmans, Musso) in connection with a restructuring plan following discontinuation of pociredir development. While the section also discloses Greg Tourangeau's departure, the bulk of the disclosure centers on compensatory arrangements—retention bonuses and severance modifications—approved by the compensation committee and board, making exec_compensation the most salient event type.
View raw filing on EDGAR →
8-K
Exec departure
confidence 72%
filed 2026-06-11
Item 5.02
Mr. Philip R. Martens retired from his positions as member and Chairman of the Board effective June 11, 2026. While the filing also discloses Mr. Venturelli's election as Chairman, the principal disclosed action centers on Martens' departure from the chairmanship—a material executive transition at the board level. The retirement of a sitting Chairman is a material event affecting corporate governance and investor assessment of the company.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Aura Biosciences' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for two proposals: election of two Class II directors (David Johnson and Teresa Marie Bitetti) and ratification of Ernst & Young LLP as the independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are characteristic of Item 5.07 disclosures and are material to investors as they confirm governance decisions and auditor appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-11
Item 5.02
Daniel Durn was appointed as Chief Financial Officer and Executive Vice President of Marvell Technology effective June 15, 2026, with a compensation package including $850,000 base salary, $1,000,000 sign-on bonus, and approximately 103,508 RSUs in equity grants.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Legence Corp. held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on five proposals: election of Class I directors (David Coghlan and Bilal Khan), advisory approval of 2026 named executive officer compensation, frequency of future advisory compensation votes (approved for annual frequency), approval of the 2026 Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 filing discloses the results of Korro Bio's 2026 annual meeting of stockholders held on June 10, 2026, including: (1) election of two Class I directors (Nessan Bermingham and Rachel Meyers) for three-year terms; (2) non-binding advisory approval of named executive officer compensation; and (3) ratification of Ernst & Young LLP as independent auditor. These are routine but material shareholder vote outcomes that affect board composition and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 8.01
Allbirds increased the maximum aggregate offering price under its at-the-market (ATM) offering program by $48.1 million of Class A common stock on June 11, 2026. This is a registered equity issuance program that will dilute existing shareholders and represents a material capital-raising activity. The filing explicitly references the prospectus supplement and registration statement, confirming this is a formal dilutive equity offering.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
IQVIA completed issuance of €950 million in senior notes on June 11, 2026, pursuant to a definitive indenture agreement. The proceeds are being used to refinance existing indebtedness, representing a material capital structure and debt financing event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 8.01
Qwest settled exchange offers on June 11, 2026, issuing approximately $1.38 billion in aggregate principal amount of new notes (6.500% Notes due 2051 and 6.750% Notes due 2052) in exchange for outstanding old notes, with consent solicitations to amend existing indentures. This represents a material debt restructuring transaction that affects the company's capital structure and financial obligations, warranting classification as a material activity involving a significant refinancing/exchange of securities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from Nkarta's June 10, 2026 annual meeting. The filing reports the outcomes of four distinct votes: election of two Class III directors (Ali Behbahani and Zachary Scheiner), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and an advisory vote on the frequency of future compensation votes. These are routine but material governance matters that inform investors of shareholder decisions.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-11
Item 4.01
The filing discloses the dismissal of Baker Tilly US, LLP as the Company's independent registered public accounting firm and the appointment of PricewaterhouseCoopers LLP as the successor auditor, both approved by the Audit Committee on June 10, 2026. This is a classic auditor change under Item 4.01, and is material because it affects the registrant's financial reporting oversight and audit quality assurance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Intuit issued $1.75 billion in aggregate principal amount of senior notes ($750M due 2031 at 4.950% and $1B due 2036 at 5.500%), with net proceeds of approximately $1.74 billion intended for general corporate purposes including potential refinancing of existing debt. While this is a material financing event affecting the registrant's capital structure and liquidity, it does not fit cleanly into the more specific event categories (not a dilutive equity issuance, not M&A activity, not a covenant breach or going-concern disclosure). The disclosure is routine debt issuance disclosure under Item 8.01, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of the Company's June 9, 2026 annual meeting of shareholders, including voting outcomes on three matters: (1) election of six trustees, where all candidates failed to meet the two-thirds vote requirement but will continue in office under Maryland law; (2) ratification of Deloitte & Touche LLP as independent auditor, which passed; and (3) an advisory say-on-pay resolution that was rejected by shareholders. The disclosure of shareholder vote results, particularly the failure of the say-on-pay proposal and the trustee election shortfall, is material to investors assessing governance and compensation practices.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Fractyl Health's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Marc Elia, Clive Meanwell, and Ian Sheffield), and (2) ratification of Ernst & Young LLP as independent auditors. All matters were approved. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-11
Item 8.01
Seagate announced a redemption of $1 billion in 3.50% Exchangeable Senior Notes due 2028, with a redemption date of September 8, 2026. This debt management action affects the company's capital structure and involves convertible debt that may result in shareholder dilution through the exchange mechanism.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-11
Item 2.02
The filing discloses J. W. Mays, Inc.'s financial results for the three and nine months ended April 30, 2026, including revenues and net loss figures with year-over-year comparisons. A press release reporting quarterly financial results is the classic earnings_release event, and Item 2.02 is the standard disclosure location for such announcements.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 7.01
The registrant announced a second quarter cash dividend of $0.45 per share via press release on June 11, 2026. While dividend declarations are routine for REITs like Chimera Investment Corp, they are material to investors as they directly affect shareholder returns and are a key metric for evaluating the company's financial health and distribution capacity. This does not fit the earnings_release category (which typically discloses quarterly/annual financial results) but represents a material capital allocation decision.
View raw filing on EDGAR →